OrbiMed Advisors KALV Position
Active7-Fund ConvergenceOrbiMed Advisors initiated a new position in KalVista Pharmaceuticals, Inc. (KALV) in Q4 2025, holding $6.2M worth of shares across 382,400 shares.
KALV is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for KVD900 600 mg in 75 days (Jun 30, 2026), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 42.9% of float with 23.1 days to cover, indicating significant bearish positioning against OrbiMed's long thesis.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
42.9%
23.1 days to cover
Frequently Asked Questions
Does OrbiMed Advisors own KALV?
Yes. As of Q4 2025, OrbiMed Advisors holds 382,400 shares of KalVista Pharmaceuticals, Inc. (KALV) valued at $6.2M. This data comes from their SEC 13F filing.
How many hedge funds own KALV?
7 specialist biotech hedge funds currently hold KALV, including Tang Capital Management, Boxer Capital, Driehaus Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy KALV?
OrbiMed Advisors's position in KALV was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's KALV position increasing or decreasing?
OrbiMed Advisors initiated a new position in KALV in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
KALVCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →